GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Current Ratio

T2 Biosystems (T2 Biosystems) Current Ratio : 0.45 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. T2 Biosystems's current ratio for the quarter that ended in Dec. 2023 was 0.45.

T2 Biosystems has a current ratio of 0.45. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If T2 Biosystems has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for T2 Biosystems's Current Ratio or its related term are showing as below:

TTOO' s Current Ratio Range Over the Past 10 Years
Min: 0.31   Med: 2.86   Max: 14.56
Current: 0.45

During the past 12 years, T2 Biosystems's highest Current Ratio was 14.56. The lowest was 0.31. And the median was 2.86.

TTOO's Current Ratio is ranked worse than
92.44% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.245 vs TTOO: 0.45

T2 Biosystems Current Ratio Historical Data

The historical data trend for T2 Biosystems's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Current Ratio Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 5.47 3.80 1.91 0.45

T2 Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 1.06 0.36 0.59 0.45

Competitive Comparison of T2 Biosystems's Current Ratio

For the Diagnostics & Research subindustry, T2 Biosystems's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Current Ratio distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Current Ratio falls into.



T2 Biosystems Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

T2 Biosystems's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=25.189/56.152
=0.45

T2 Biosystems's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=25.189/56.152
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


T2 Biosystems  (NAS:TTOO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


T2 Biosystems Current Ratio Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421